Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.67 |
| ▸ | KIF5B | P33176 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | BRAF | P15056 | 8/20 | 0.54 |
| ▸ | RAF1 | P04049 | 4/20 | 0.54 |
| ▸ | MET | P08581 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011413 | 0.95 | KDR (0.67) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL1012448 | 0.90 | KDR (0.73) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL13680234 | 0.87 | KDR (0.61) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL4025375 | 0.86 | KDR (0.67) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL1011750 | 0.84 | KDR (0.64) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL1011699 | 0.84 | KDR (0.64) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL16692911 | 0.84 | KDR (0.65) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL1015360 | 0.82 | KDM1A (0.66) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL15084645 | 0.81 | KDR (0.57) | KDRRETKIF5BEGFRLCK | |
| SCHEMBL18023873 | 0.81 | KDR (0.61) | KDRRETKIF5BEGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2016-07-14 | — | — | US | disclosed |
| US-9320739-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| EP-2947072-A1 | 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES | Ambit Biosciences Corporation (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2268623-B1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8969587-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2014-02-13 | — | — | US | disclosed |
| US-8618289-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | KDR 982/4885RET 75/4885KIF5B 3262/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDR 2031/4885RET 46/4885KIF5B 3347/4885 |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDR 982/4885RET 75/4885KIF5B 3262/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDR 982/4885RET 75/4885KIF5B 3262/4885 |
| US-20150246042-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDR 982/4885RET 75/4885KIF5B 3262/4885 |
| US-20140045868-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDR 982/4885RET 75/4885KIF5B 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.